Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 0.64 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.64 |
| ▸ | JAK2 | O60674 | 1/20 | 0.64 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.64 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.64 |
| ▸ | PAK4 | O96013 | 1/20 | 0.64 |
| ▸ | ABL1 | P00519 | 1/20 | 0.64 |
| ▸ | CSF1R | P07333 | 1/20 | 0.64 |
| ▸ | RET | P07949 | 1/20 | 0.64 |
| ▸ | IGF1R | P08069 | 1/20 | 0.64 |
| ▸ | MET | P08581 | 1/20 | 0.64 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.64 |
| ▸ | PIM1 | P11309 | 1/20 | 0.64 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.64 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.64 |
| ▸ | PRKACA | P17612 | 1/20 | 0.64 |
| ▸ | FLT1 | P17948 | 1/20 | 0.64 |
| ▸ | LTK | P29376 | 1/20 | 0.64 |
| ▸ | GRK5 | P34947 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12068009 | 0.79 | PARP1 (0.66) | PARP1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL16097896 | 0.78 | PARP1 (0.64) | PARP1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL1387233 | 0.78 | PARP1 (0.64) | PARP1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL29443212 | 0.78 | PARP1 (1.00) | PARP1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL5370073 | 0.78 | PARP1 (1.00) | PARP1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL2447579 | 0.78 | PARP1 (1.00) | PARP1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL12747755 | 0.78 | PARP1 (0.64) | PARP1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL13857872 | 0.78 | PARP1 (0.64) | PARP1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL21895445 | 0.78 | PARP1 (1.00) | PARP1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL12068152 | 0.78 | PARP1 (0.64) | PARP1AURKADAPK3JAK2PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118996447-A | Phosphine-oxide substituted quinoxaline quinazolinone compound, preparation method and application thereof | 南阳师范学院 | 2024-11-22 | — | — | CN | claimed |
| EP-3154962-A2 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2017-04-19 | — | — | EP | claimed |
| WO-2015191754-A2 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2015-12-17 | — | — | WO | claimed |
| WO-2025077770-A1 | FUSED RING COMPOUND AND USE THEREOF IN KRAS INHIBITOR | 成都海博为药业有限公司 | 2025-04-17 | — | — | WO | disclosed |
| EP-4305037-B1 | KRAS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-02-26 | — | — | EP | disclosed |
| CN-118996447-A | Phosphine-oxide substituted quinoxaline quinazolinone compound, preparation method and application thereof | 南阳师范学院 | 2024-11-22 | — | — | CN | disclosed |
| US-20240217982-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-07-04 | — | — | US | disclosed |
| CN-115260164-B | Preparation method, structural composition and application of novel 4 (3H) -quinazolinone analogue in antitumor drugs | 杭州星鳌生物科技有限公司 | 2024-03-26 | — | — | CN | disclosed |
| EP-4305037-A1 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022233253-A1 | METHOD FOR PREPARING NEW 4(3H)-QUINAZOLINONE ANALOG, STRUCTURAL COMPOSITION THEREOF, AND USE THEREOF IN ANTITUMOR DRUGS | 杭州星鳌生物科技有限公司 | 2022-11-10 | — | — | WO | disclosed |
| CN-115260164-A | Preparation method and structural composition of novel 4 (3H) -quinazolinone analogue and application of analogue in antitumor drugs | 杭州星鳌生物科技有限公司 | 2022-11-01 | — | — | CN | disclosed |
| WO-2022192790-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-15 | — | — | WO | disclosed |
| CN-107337646-B | Method for synthesizing quinazolinone derivative by using methanol as raw material | 南京理工大学 | 2020-04-07 | — | — | CN | disclosed |
| US-20190345146-A1 | NITROGEN CONTAINING BICYCLIC DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-11-14 | — | — | US | disclosed |
| EP-3339307-A1 | NITROGEN CONTAINING BICYCLIC DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | Laboratorios del Dr. Esteve, S.A. (ES) | 2018-06-27 | — | — | EP | disclosed |
| CN-107337646-A | A kind of method using methanol as Material synthesis Quinazol derivative | 南京理工大学 | 2017-11-10 | — | — | CN | disclosed |
| EP-3154962-A2 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015191754-A2 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2015-12-17 | — | — | WO | disclosed |
| WO-2012014109-A1 | HETEROCYCLIC SULFONAMIDES AS INHIBITORS OF TRANSFER RNA SYNTHETASE FOR USE AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217982-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | PARP1 404/4885AURKA 685/4885DAPK3 345/4885 |
| US-20190345146-A1 | NITROGEN CONTAINING BICYCLIC DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | CACNA1B, CACNA1G, CACNA1D | PARP1 2338/4885AURKA 4157/4885DAPK3 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.